Hypertensive Cardiopathy
Conditions
Interventions
Experimental group:Western medicine standard treatment combined with Qianyang Yuyin Granules
Sponsors
Affiliated Hospital of Nanjing University of Chinese Medicine
Eligibility
Sex/Gender
All
Age
60 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. In line with TCM syndrome of yin deficiency and yang hyperactivity; 2. Aged 60 to 80 years; 3. Patients with primary hypertension of grade 1-2 ; 4. Left Ventricular hypertrophy was consistent with ECG Sokolow-lyon voltage >3.8mV or Cornell product >244mV·ms, or echocardiographic Left Ventricular Mass Index (LVMI): male =115g/m2, female =95g/m2; 5. ARB or CCB drugs can reduce blood pressure to meet the requirements, systolic blood pressure (SBP) =140mmHg and diastolic blood pressure (DBP) =90mmHg; 6. Sign the informed consent for entry into the study.
Exclusion criteria
Exclusion criteria: 1. Secondary hypertension; 2. Complicated with serious cardiovascular target organ complications, such as acute myocardial infarction, stroke, grade IV heart failure, malignant arrhythmia, etc.; 3. Other Chinese and Western drugs have been used to treat essential hypertension; 4. Patients with definite contraindications to the use of ARB or CCB drugs; 5. Patients with significantly abnormal liver function; 6. Unable to give full informed consent due to intellectual or behavioral disabilities; 7. Suspected or confirmed history of alcohol and drug abuse; 8. Other diseases that reduce the possibility of enrollment or complicate enrollment, such as frequent changes in the working environment, are likely to cause loss of follow-up according to the judgment of the researcher; 9. Allergies, such as allergies to two or more drugs or foods; or known allergies to the ingredients of the drug; 10. Patients who are participating in clinical trials of other drugs.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Diastolic ventricular septal thickness;Left ventricular posterior wall thickness (LVPWd);Left ventricular end-diastolic diameter (LVIDd);Early diastolic peak (E);Late diastolic peak;Left ventricular ejection fraction;E/e’;E/A;Left ventricular mass;Left ventricular mass index; | — |
Secondary
| Measure | Time frame |
|---|---|
| tumor necrosis factor-a ;intercellular adhesion molecule-1;vascular cell adhesion molecule-1;monocyte chemotactic protein 1 ;Interleukin-1ß;Interleukin-6;8-hydroxydeoxyguanosine;reactive oxygen species ;superoxide dismutase ;glutathione peroxidase;malondialdehyde ; | — |
Countries
China
Contacts
Public ContactFangYuan
Affiliated Hospital of Nanjing University of Chinese Medicine
Outcome results
None listed